NDAORALTABLET
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
1 and 2 (JAK1/JAK2) and mutant JAK2, which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Momelotinib and its major human circulating metabolite, M21, have higher inhibitory activity for JAK2 compared to JAK3 and…
Clinical Trials (5)
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
Started Nov 2026
40 enrolled
Myelofibrosis
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Started Mar 2026
18 enrolled
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromesMyeloproliferative Overlap Neoplasms+1 more
Momelotinib During and After HCT in Myelofibrosis
Started Jan 2026
28 enrolled
MyelofibrosisHematopoietic Cell Transplantation (HCT)
Momelotinib in VEXAS Syndrome
Started Nov 2025
57 enrolled
VEXAS SyndomeMyelo Dysplastic Syndrome
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Started Jun 2025
80 enrolled
Myelodysplastic Syndromes
Loss of Exclusivity
LOE Date
Dec 2, 2040
179 months away
Patent Expiry
Dec 2, 2040
Exclusivity Expiry
Sep 15, 2030